A major Aussie university and ASX-listed company will deploy psychedelic drugs to treat binge-eating in a world-first clinical trial. Experimental healthcare company Tryptamine Therapeutics announced ...

Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks Tryptamine Therapeutics has released ...

Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks Tryptamine Therapeutics has ...

Psychedelics such as psilocybin are showing promise as potential therapeutics for psychiatric disorders such as depression, with rapid and long-lasting effects. Investigations into their mechanism of ...

Tryptamine trial partner Swinburne University receives key permit for world-first clinical trial of IV-psilocin (TRP-8803) to treat binge eating disorder Permit allows Tryptamine to start supply of ...

Tryptamine Therapeutics has reached a milestone in development of its novel IV-infused psilocin formulation TRP-8803, with the drug meeting all phase 1b study objectives. Tryptamine Therapeutics ...

Placement cornerstoned by Merchant Biotech Fund and biotech investor Dr Daniel Tillett, who will join the board Funds to accelerate clinical trial strategy for lead program IV-infused psilocin ...

Tryptamine has secured a key regulatory approval to supply its IV-psilocin drug to Swinburne University for a world-first binge eating disorder trial. Tryptamine trial partner Swinburne University ...